Last reviewed · How we verify
Exposed group
At a glance
| Generic name | Exposed group |
|---|---|
| Also known as | Patients receiving DOAC |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus (PHASE1)
- Conventional vs Pulsed RF in Coccydynia (NA)
- A Machine Learning Prediction Model for Postoperative Acute Kidney Injury in Non-Cardiac Surgery Patients
- Music Induced Modulation of Pressure Pain Sensitivity and Affective Valence, Comparing Silence and Self-Selected Levantine Music (NA)
- SMILE Trial - Imaging Sub-Study
- Adaptation and RCT of Written Exposure Therapy for Adolescents (NA)
- Median and Ulnar Nerve Function in Tattoo Artists
- Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Exposed group CI brief — competitive landscape report
- Exposed group updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI